News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Archemix Corporation Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech


2/19/2008 8:49:53 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it will receive a milestone payment from its collaborator Ophthotech Corp. The milestone payment has been triggered by Ophthotech’s enrollment of the first volunteer in a Phase 1 study of E10030, an anti-platelet derived growth factor (PDGF) aptamer which is being developed for age related macular degeneration (AMD). The Phase 1 trial is testing the safety and tolerability of E10030 in combination with an anti-vascular endothelial growth factor (VEGF) agent. This trial will enroll up to a maximum of 36 patients.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES